Eli Lilly’s shares rose nearly 5% to $1,170 apiece in premarket trading as the company reported $23 billion in revenue for the second quarter. The company’s market cap is $1.02 trillion as of the end of July.
Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1